I. Ethical dilemmas
The most fundamental ethical dilemma surrounding gene-editing technologies is not merely that they are risky, but that the extent and nature of those risks remain profoundly unknown. CRISPR-Cas9 and other editing tools have undoubtedly unlocked immense therapeutic potential—offering new hope for immunotherapy, rare disease treatment, and the prevention of genetic disorders. Yet this promise is shadowed by the disturbing fact that we lack sufficient empirical evidence regarding the full range of potential harms.
In traditional clinical trials—for example, Phase II oncology studies—substantial risks such as death or irreversible side effects are accepted under the condition of informed consent. These interventions are ethically justified because they are grounded in a clear benefit-risk ratio and are often the most viable or superior option available. This raises the question: shouldn’t gene-editing technologies be held to the same standard if informed consent is obtained?
The answer lies in a critical distinction. With CRISPR, the very magnitude and character of the risks are not only unclear but also immeasurable at present. Unlike technologies whose dangers can be quantified, gene-editing operates within an epistemic void—rendering any predictive or preparatory response inherently impossible. This transforms the issue from one of quantitative comparison to one of qualitative uncertainty.
Such uncertainty directly undermines a core ethical principle: an action can only be morally justified if one is capable of assuming responsibility for its outcomes. In vaccine trials, for instance, adverse effects are anticipated and addressed through institutional accountability and legal frameworks. In contrast, gene editing in embryos defies such structures—its consequences are both unpredictable and irreversible, and the subject (the embryo) cannot grant consent in any meaningful sense.
Therefore, the absence of both predictive knowledge and moral accountability renders the very criteria by which we evaluate the technology’s ethical permissibility inert. Even with good intentions, informed consent, and potential benefits, a technological intervention devoid of responsible agency cannot meet the standards of ethical justification.
The Ethical Problem of Arbitrary Intervention
In addition to the epistemic uncertainty surrounding CRISPR, a more profound ethical dilemma lies in the inherently arbitrary nature of human intervention. Here, arbitrariness refers not merely to the fact that humans are the agents of action, but to the asymmetrical and irreversible imposition of life-defining conditions onto another being. What intensifies this issue is that the target of such intervention often lacks any capacity for autonomy—most notably, the embryo or fetus. The use of gene editing is likely to be applied at early stages of development, when the individual has no means of consent or resistance. Moreover, the consequences are not limited to a single lifetime, but are potentially heritable, cascading across future generations.
This transforms the editor into an architect of another’s entire biological existence, not simply a medical actor offering treatment. While eliminating genetic diseases may appear benevolent on the surface, the act itself is ontologically coercive: it selects and fixes the very conditions under which a person will exist. Philosophically, this shifts the relationship from one of subject-to-subject to one of subject-to-object—treating a human being not as an end in themselves, but as a means to a preconceived ideal.
Even when such interventions are justified by intentions to provide a “better life,” they rest on a presupposition that human value is conditional—that certain traits or characteristics are inherently preferable, and others are deficiencies to be corrected. This logic risks collapsing the intrinsic worth of individuals into a framework of optimization, effectively reducing the human subject to a customizable product.
Such thinking is already widespread in contemporary society: body dysmorphia, social comparison, and obsessive self-optimization are all symptoms of a deeper cultural malaise in which existence itself is treated as evaluable. Gene editing, in this sense, becomes not a radical leap forward, but a technological extension of the same instrumental mindset.
Of course, using CRISPR to prevent devastating genetic diseases may be seen as alleviating suffering, not denying existence. Yet this too raises a critical question: Where do we draw the line? Once we justify editing for fatal conditions, how do we stop the logic from expanding to include autism, color blindness, physical appearance, or even personality traits? Without a clearly defined threshold, we risk rendering all deviations from the norm as pathological.
Ultimately, even when framed with good intentions, arbitrary intervention carries a latent violence. It reflects a silent assumption: that existence must be justified—not by the mere fact of being, but by conformity to selected ideals.
Societal Implications: Accessibility and Distributive Justice
While CRISPR-based gene editing holds great promise in treating severe diseases and improving human quality of life, its implementation raises an essential ethical question: who will benefit from this technology, and on what basis?
Technologies may be universal in principle, but the right to access them has rarely been so. In its early stages, CRISPR is expected to be expensive, and this cost barrier is likely to limit its availability to a privileged minority. The issue at stake is not merely economic; rather, it signals the emergence of a biological stratification, where “edited humans” and “non-edited humans” might differ not only in health outcomes, but in social recognition, opportunity, and status. If gene editing contributes to such disparities, it becomes a driver of structural injustice, not just scientific progress.
What makes this concern even more pressing is the fact that much of CRISPR’s research and development has been funded by public institutions and taxpayer money. To allow private actors to monopolize and profit from the technology without ensuring equitable access undermines its moral legitimacy. A technology born from public investment but reserved for private gain is ethically indefensible.
Additionally, disparities in access are not confined to economic class—they extend across borders. Genetically fortified crops and treatments might be theoretically able to address malnutrition or disease in low-income regions, but whether they will reach such communities—especially under regimes with political or economic instability—remains uncertain.
Ultimately, CRISPR is not simply a therapeutic tool, but a transformative force capable of reshaping the very conditions of human life. Without a critical examination of who gets to benefit, and how, gene editing risks becoming a technology of privilege, reinforcing and institutionalizing existing inequalities.
II. Discussion
- One of the biggest ethical questions about CRISPR is this: can we really justify stepping in and changing nature, especially when our past actions already caused so much damage? I thought about this deeply when I read The Prediction of the Honeybee as part of a youth journalism program. The book showed how human greed for efficiency in farming—like using too many pesticides—led to the collapse of bee populations.
And this isn’t just theory. In spring 2025, around 62% of commercial honeybee colonies in the U.S. disappeared. That’s about 72% of all bees in the country—over 1.6 million hives gone. The result? More than $600 million in losses, and serious threats to food production, since bees play a key role in pollinating crops.
Now, some suggest using CRISPR to engineer bees that are more resistant to disease or environmental stress. But here’s the irony: the same kind of human interference that caused the collapse is now being used to “save” the bees. It feels like we’re repeating the same mistake.
If we wish to ethically justify this form of intervention, it is not enough to act with good intentions—we must be able to assume full responsibility for its outcomes. This responsibility entails more than moral accountability; it requires predictive foresight, concrete control over consequences, and an institutional framework capable of addressing harm if and when it arises. However, in the case of gene editing wild species or releasing modified insects into ecosystems, such prerequisites are fundamentally lacking. Without these structural safeguards, any claim to ethical legitimacy remains precarious at best.
So what do we do? We can’t just avoid action forever—but we also can’t act like we’ve learned nothing. If we’re going to use CRISPR in ecosystems, it needs to be with extreme care, strict rules, and a deep awareness of how easily we could make things worse. Otherwise, we’re not fixing anything—we’re just running in circles, repeating a cycle of causing and fixing problems.
III. Conclusion
CRISPR-Cas9 represents both a triumph of scientific ingenuity and a formidable ethical puzzle. Its unprecedented ability to edit genes with precision offers revolutionary possibilities in medicine, agriculture, and beyond. Yet, as this paper has shown, technological capability alone is not sufficient to justify implementation. Moral justification requires more than good intentions; it demands a tangible structure of accountability—entailing foresight, control, and responsibility for the consequences of intervention. As the bee case illustrates, interventions pursued with good intentions can still mirror the same dynamics of domination and ecological disturbance that initially gave rise to the problem.
Therefore, we must resist the temptation to treat CRISPR as a universal remedy. Instead, its adoption should be guided by a framework of moral responsibility that is as rigorous and adaptive as the technology itself. This includes transparent governance structures, precautionary scientific oversight, and a constant reevaluation of whether the intervention serves the common good or merely reinforces existing inequalities.
Ultimately, CRISPR is not simply a question of what we can do, but what we should do. The path forward demands a fusion of scientific excellence and ethical vigilance—a dual commitment to innovation and humility. Only then can CRISPR move from a tool of disruption to an instrument of responsible progress.
